查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134970

全球雙極性情感障礙治療產品線分析 - 2026 年（第二季洞察與臨床試驗）

Global Bipolar Disorder Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

該領域的研究和開發正在迅速超越傳統的情緒穩定劑和抗精神病藥物的框架，開發人員專注於創新的作用機制、改進的安全性、增強的長期療效和個性化的治療方法。

雙極性情感障礙是一種慢性精神疾病，其特徵是躁狂、輕躁症和憂鬱症交替發作，導致顯著的功能障礙和生活品質下降。儘管目前已有鋰鹽、抗驚厥藥物、非典型抗精神病藥物和輔助抗憂鬱症等成熟療法，但許多患者仍面臨復發、治療抵抗、認知障礙和藥物相關副作用等問題。因此，製藥和生技公司正積極研發新一代療法，旨在改善症狀控制、降低復發率並提高長期用藥依從性。藥物研發管線分析能夠全面深入了解臨床實驗中的療法、其研發階段、作用機制、申辦方活動、監管申報以及商業化潛力。

市場促進因素

創新精神病治療的需求日益成長

  • 推動研發管線擴張的主要因素之一是未被滿足的醫療需求不斷成長，尤其是針對雙極性憂鬱症、維持治療以及難治性雙相情感障礙的療法。由於現有療法的局限性，研發人員正在尋找新的治療靶點，以提高療效並減少副作用。

加大神經科學研究的投資

  • 製藥公司、生技公司和學術機構正不斷增加對神經科學研究的投入。神經生物學、遺傳學和分子精神病學的進步正在加速發現針對多種參與情緒調節的神經通路的創新候選藥物。

開發新的作用機制

  • 隨著麩胺酸、血清素、多巴胺、GABA能系統、神經可塑性、晝夜節律、發炎和其他新興生物學路徑等標靶療法的研發，雙相情感障礙的治療方案正變得日益多元化。這些新療法旨在改善治療效果，同時最大限度地減少現有療法相關的代謝、神經和認知方面的副作用。

有利的法規環境

  • 監管機構持續鼓勵精神藥物研發領域的創新，包括加速核准程序、視情況授予突破性療法認定、進行合作研發計畫。這些措施支持對雙極性情感障礙新療法的持續投入，並加速臨床研發進程。

市場限制因素

複雜的臨床開發

  • 雙相情感障礙表現出顯著的臨床異質性，這給患者選擇、終點評估和長期療效評估帶來了挑戰。症狀表現和疾病進展的差異進一步增加了藥物研發的複雜性。

高昂的臨床開發成本

  • 精神藥物的研發需要大規模的臨床試驗，包括長期的追蹤期、多個療效終點和全面的安全性評估，這導致了巨大的研發成本。

高管道脫落率

  • 在中樞神經系統藥物的研發過程中，由於在證明臨床療效、保持安全性以及獲得監管部門批准方面存在諸多挑戰，失敗率仍然相對較高，這增加了研發公司的投資風險。

深入了解製藥研發管線和技術

  • 全球雙極性情感障礙治療藥物研發管線可依研發階段、作用機轉、治療方法、適應症及地區分類。
  • 依研發階段分類，研發管線包括臨床前計畫、I期、II期、III期臨床試驗以及已提交核准或正在接受監管審查的藥物。早期計畫在正在進行的研究中佔據相當大的比例，這反映了我們對創新治療標靶的持續探索。
  • 從作用機轉來看，此研發管線涵蓋麩胺酸調變器、血清素療法、多巴胺調變器、GABA療法、神經可塑性療法、晝夜節律調變器、抗發炎藥物以及多標靶治療方法。人們越來越關注能夠有效治療雙相情感障礙憂鬱症期並最大限度降低誘發躁症發作風險的療法。
  • 從治療模式來看，研發管線涵蓋小分子化合物、生技藥品、RNA療法、細胞和基因療法以及聯合治療。雖然小分子化合物仍佔據研發管線的大部分，但生技藥品和先進治療平台正在逐漸擴大。
  • 從適應症來看，目前正在進行臨床實驗的療法主要針對雙極性憂鬱症、急性躁鬱症、維持治療、混合發作以及難治性雙相情感障礙。由於雙極性憂鬱症存在巨大的未滿足需求和有限的治療選擇，因此仍然是研發管線投資最大的領域。
  • 人工智慧、電腦輔助藥物發現、生物標記識別、基因組醫學、數位生物標記、分散式臨床試驗和真實世界證據等方面的技術進步正在改善標靶識別、患者分層、臨床試驗效率和監管決策。

管道開發趨勢

  • 隨著研發人員努力尋找能夠兼顧提高耐受性和持續控制症狀的治療方法，雙極性情感障礙的治療研發管線正在經歷重大變革。

主要發展趨勢如下：

  • 擴大雙極性憂鬱症的治療選擇。
  • 開發旨在降低復發頻率的維持治療方案。
  • 人們對精準精神病學越來越感興趣，精準精神病學利用生物標記和基因組分析。
  • 基於新型神經傳導物質和神經元可塑性機制的療法研究。
  • 將人工智慧應用於藥物發現和臨床開發。
  • 開發旨在提高療效和患者用藥依從性的聯合治療。
  • 製藥公司、生技公司、學術機構和研究機構之間的策略夥伴關係正在加速創新，並不斷加強研發管線的開發。

區域趨勢

  • 北美憑藉其先進的神經科學研究基礎設施、製藥業的巨額投資、廣泛的臨床試驗活動以及支持性的法律規範，仍然是雙相情感障礙治療領域領先的地區。
  • 歐洲透過合作研究、強大的學術網路以及對精神疾病創新療法的持續投入，在精神病學領域繼續發揮至關重要的作用。
  • 預計在預測期內，亞太地區將經歷最快的成長，這主要得益於生物技術能力的擴張、醫療保健投資的增加、人們對精神疾病的認知不斷提高，以及中國、日本、韓國、印度和澳洲等國參與跨國臨床試驗的增加。
  • 在拉丁美洲、中東和非洲，由於醫療保健基礎設施的改善、診斷率的提高以及國際臨床研究合作的擴大，精神病學研究正在逐步擴展。

競爭格局

  • 雙相情感障礙治療藥物的研發競爭非常激烈，跨國製藥公司、生物技術公司、學術研究機構、合約研究組織 (CRO) 以及新興神經科學領域的創新者都在參與競爭。
  • 為了提升產品線的競爭力，研發公司正加大對差異化治療機制、精準醫療技術、人工智慧驅動的藥物發現以及與數位醫療的融合等方面的投資。策略聯盟、授權協議、併購以及共同開發夥伴關係持續加速創新，同時拓展全球研發能力。
  • 與傳統療法相比，競爭越來越集中在那些能夠改善憂鬱症狀、預防復發、增強認知功能並提供更高長期安全性的療法。

未來展望

  • 雙相情感障礙治療領域未來的發展預計將受到神經科學、人工智慧、生物標記發現、基因組學和精準精神病學等領域持續進步的推動。新的療法有望提供更個人化的治療方案，同時提高療效、耐受性和長期疾病管理水平。
  • 隨著對雙相情感障礙的科學認知不斷發展，未來的研發管線資產可能會集中於該疾病的生物學、神經可塑性、發炎機制和個人化醫療，從而為製藥業的創新和商業化創造重大機會。

結論

全球雙相情感障礙治療產品線分析市場預計將持續成長至2035年，主要驅動力包括精神藥物研發投入的增加、神經科學研究的拓展、對雙極性憂鬱症日益成長的關注以及精準醫療的不斷進步。儘管複雜的臨床開發、高失敗率和巨額研發成本等挑戰依然存在，但新型治療機制、人工智慧、生物標記研究和個人化精神病學等領域的持續創新有望改變未來的治療格局，為患者、醫療專業人員和製藥公司創造新的機會。

本報告的主要益處

  • 深入分析：對全球雙相情感障礙治療產品線、臨床實驗中的療法以及未來治療趨勢進行全面評估。
  • 競爭格局：對管道資產、開發商、營運機制和策略定位進行詳細評估。
  • 市場促進因素與未來趨勢：科學創新、監管趨勢與商業化機會分析。
  • 實用建議：策略見解，以支援許可、合作夥伴關係評估、投資規劃、投資組合最佳化和產品開發。
  • 適合廣泛讀者：本出版物為製藥公司、生物技術公司、投資者、研究人員、受託研究機構(CRO)、醫療保健專業人員和政策制定者提供有價值的資訊。

我們的報告的應用領域

  • 管線基準分析、藥物發現策略、競爭情報分析、授權協議評估、合作夥伴選擇、投資分析、投資組合管理、商業化規劃、監管策略制定以及未來成長機會的識別。

調查範圍

  • 歷史資料涵蓋 2021 年至 2025 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 從研發階段、作用機轉、治療方法、適應症和地區等方面對全球雙極性情感疾患治療產品線進行全面分析。
  • 對在臨床實驗藥物、臨床開發進展、監管里程碑和研發管線成熟度進行評估。
  • 分析贊助商趨勢、企業投資組合、授權協議、策略聯盟、併購和競爭定位。
  • 評估新興技術、創新趨勢、成功率、商業化潛力以及未來發展機會。
  • 策略性展望涵蓋未滿足的需求、上市計劃、市場機會以及到 2035 年的未來治療發展。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：雙極性情感障礙的管道動態

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Johnson & Johnson Innovative Medicine
    • Vanda Pharmaceuticals
    • Otsuka Pharmaceutical
    • Alzamend Neuro
    • AbbVie
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 雙極性憂鬱症
    • 急性躁鬱症
    • 維持治療
    • 難治性雙極性情感障礙
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 對贊助商和合作研究機構的分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Johnson & Johnson Innovative Medicine
  • Vanda Pharmaceuticals
  • Otsuka Pharmaceutical
  • Alzamend Neuro
  • AbbVie

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008935

The pipeline is rapidly evolving beyond conventional mood stabilizers and antipsychotics, with developers focusing on innovative mechanisms of action, improved safety profiles, enhanced long-term efficacy, and personalized treatment approaches.

Bipolar disorder is a chronic psychiatric disorder characterized by alternating episodes of mania, hypomania, and depression, resulting in significant functional impairment and reduced quality of life. Despite the availability of established therapies such as lithium, anticonvulsants, atypical antipsychotics, and adjunctive antidepressants, many patients continue to experience relapse, treatment resistance, cognitive impairment, and medication-related adverse effects. Consequently, pharmaceutical and biotechnology companies are actively developing next-generation therapies that improve symptom control, reduce relapse rates, and enhance long-term treatment adherence. Drug pipeline analysis provides comprehensive insights into investigational therapies, development stages, mechanisms of action, sponsor activities, regulatory progress, and commercialization potential.

Market Drivers

Growing Demand for Innovative Psychiatric Therapies

  • One of the major factors driving pipeline expansion is the increasing need for therapies capable of addressing unmet clinical needs, particularly bipolar depression, maintenance therapy, and treatment-resistant bipolar disorder. Current treatment limitations have encouraged developers to investigate novel therapeutic targets capable of providing improved efficacy with fewer adverse effects.

Expanding Investment in Neuroscience Research

  • Pharmaceutical companies, biotechnology firms, and academic institutions continue to increase investment in neuroscience research. Advances in neurobiology, genetics, and molecular psychiatry have accelerated the discovery of innovative drug candidates targeting multiple neurological pathways involved in mood regulation.

Development of Novel Mechanisms of Action

  • The bipolar disorder pipeline is becoming increasingly diversified through the development of therapies targeting glutamatergic, serotonergic, dopaminergic, GABAergic, neuroplasticity, circadian rhythm, inflammatory, and other emerging biological pathways. These novel approaches aim to improve treatment outcomes while minimizing metabolic, neurological, and cognitive adverse effects associated with existing therapies.

Favorable Regulatory Environment

  • Regulatory agencies continue to encourage innovation in psychiatric drug development through expedited review pathways, breakthrough therapy designation where applicable, and collaborative development programs. These initiatives support continued investment in novel bipolar disorder therapies and accelerate clinical development.

Market Restraints

Complex Clinical Development

  • Bipolar disorder presents considerable clinical heterogeneity, making patient selection, endpoint evaluation, and long-term efficacy assessment challenging. Variability in symptom presentation and disease progression increases the complexity of drug development.

High Clinical Development Costs

  • Psychiatric drug development requires extensive clinical trials with long follow-up periods, multiple efficacy endpoints, and comprehensive safety evaluations, resulting in substantial research and development expenditures.

High Pipeline Attrition Rates

  • Central nervous system drug development continues to experience relatively high failure rates due to challenges in demonstrating clinical efficacy, maintaining safety, and achieving regulatory approval, increasing investment risk for developers.

Drug Pipeline and Technology Insights

  • The global bipolar disorder drug pipeline can be segmented by development phase, mechanism of action, therapeutic modality, indication, and geography.
  • By development phase, the pipeline includes preclinical programs, Phase I, Phase II, Phase III, and filed or under regulatory review assets. Early-stage programs account for a significant proportion of ongoing research, reflecting continued exploration of innovative therapeutic targets.
  • By mechanism of action, the pipeline includes glutamatergic modulators, serotonergic therapies, dopaminergic modulators, GABAergic therapies, neuroplasticity-focused therapies, circadian rhythm modulators, anti-inflammatory agents, and multi-target therapeutic approaches. Increasing emphasis is being placed on therapies capable of effectively treating bipolar depression while minimizing the risk of inducing manic episodes.
  • By therapeutic modality, the pipeline includes small molecules, biologics, RNA therapeutics, cell and gene therapies, and combination therapies. Small molecules continue to dominate the pipeline, while biologics and advanced therapeutic platforms are gradually expanding.
  • By indication, investigational therapies target bipolar depression, acute mania, maintenance therapy, mixed episodes, and treatment-resistant bipolar disorder. Bipolar depression remains the largest area of pipeline investment due to its significant unmet clinical need and limited treatment options.
  • Technological advances in artificial intelligence, computational drug discovery, biomarker identification, genomic medicine, digital biomarkers, decentralized clinical trials, and real-world evidence are improving target identification, patient stratification, clinical trial efficiency, and regulatory decision-making.

Pipeline Development Trends

  • The bipolar disorder pipeline is undergoing significant transformation as developers pursue therapies that provide durable symptom control with improved tolerability.

Key development trends include:

  • Expansion of therapies targeting bipolar depression.
  • Development of maintenance therapies designed to reduce relapse frequency.
  • Increasing focus on precision psychiatry using biomarkers and genomic profiling.
  • Investigation of therapies with novel neurotransmitter and neuroplasticity mechanisms.
  • Integration of artificial intelligence into drug discovery and clinical development.
  • Development of combination therapies designed to improve efficacy and patient adherence.
  • Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and research organizations continue to accelerate innovation and strengthen pipeline development.

Regional Insights

  • North America remains the leading region for bipolar disorder drug development due to advanced neuroscience research infrastructure, strong pharmaceutical investment, extensive clinical trial activity, and supportive regulatory frameworks.
  • Europe continues to play an important role through collaborative psychiatric research, strong academic networks, and increasing investment in innovative mental health therapies.
  • Asia-Pacific is expected to experience the fastest growth during the forecast period owing to expanding biotechnology capabilities, increasing healthcare investment, growing awareness of mental health disorders, and rising participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.
  • Latin America and the Middle East & Africa are gradually expanding psychiatric research through improvements in healthcare infrastructure, increasing diagnosis rates, and growing international clinical research collaborations.

Competitive Landscape

  • The bipolar disorder drug pipeline is highly competitive and includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and emerging neuroscience innovators.
  • Developers are investing in differentiated therapeutic mechanisms, precision medicine technologies, artificial intelligence-enabled drug discovery, and digital health integration to strengthen pipeline competitiveness. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships continue to accelerate innovation while expanding global research capabilities.
  • Competition is increasingly centered on therapies that improve depressive symptoms, prevent relapse, enhance cognitive outcomes, and deliver better long-term safety compared with conventional treatment options.

Future Outlook

  • The future of the bipolar disorder drug pipeline is expected to be driven by continued advances in neuroscience, artificial intelligence, biomarker discovery, genomics, and precision psychiatry. Emerging therapies are expected to offer more individualized treatment approaches while improving efficacy, tolerability, and long-term disease management.
  • As scientific understanding of bipolar disorder continues to evolve, future pipeline assets are likely to focus on disease biology, neuroplasticity, inflammatory mechanisms, and personalized medicine, creating significant opportunities for pharmaceutical innovation and commercialization.

Conclusion

The global Bipolar Disorder Drug Pipeline Analysis market is expected to experience sustained growth through 2035, supported by increasing investment in psychiatric drug development, expanding neuroscience research, growing focus on bipolar depression, and continuous advances in precision medicine. Although challenges related to complex clinical development, high attrition rates, and substantial research costs remain, ongoing innovation in novel therapeutic mechanisms, artificial intelligence, biomarker research, and personalized psychiatry is expected to transform the future treatment landscape and provide new opportunities for patients, healthcare providers, and pharmaceutical companies.

Key Benefits of this Report

  • Insightful Analysis: Comprehensive assessment of the global bipolar disorder drug pipeline, investigational therapies, and future treatment trends.
  • Competitive Landscape: Detailed evaluation of pipeline assets, developers, mechanisms of action, and strategic positioning.
  • Market Drivers and Future Trends: Analysis of scientific innovation, regulatory developments, and commercialization opportunities.
  • Actionable Recommendations: Strategic insights supporting licensing, partnership evaluation, investment planning, portfolio optimization, and product development.
  • Caters to a Wide Audience: Valuable for pharmaceutical companies, biotechnology firms, investors, researchers, contract research organizations, healthcare providers, and policymakers.

What Businesses Use Our Reports For

  • Pipeline benchmarking, drug development strategy, competitive intelligence, licensing evaluation, partnership identification, investment analysis, portfolio management, commercialization planning, regulatory strategy development, and identification of future growth opportunities.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global bipolar disorder drug pipeline by development phase, mechanism of action, therapeutic modality, indication, and geography
  • Evaluation of investigational drugs, clinical development progress, regulatory milestones, and pipeline maturity
  • Analysis of sponsor landscape, company portfolios, licensing agreements, strategic collaborations, mergers and acquisitions, and competitive positioning
  • Assessment of emerging technologies, innovation trends, probability of success, commercialization potential, and future pipeline opportunities
  • Strategic outlook covering unmet medical needs, launch timelines, market opportunities, and future therapeutic developments through 2035

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. BIPOLAR DISORDER PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Johnson & Johnson Innovative Medicine
    • 5.1.2. Vanda Pharmaceuticals
    • 5.1.3. Otsuka Pharmaceutical
    • 5.1.4. Alzamend Neuro
    • 5.1.5. AbbVie
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Bipolar Depression
    • 5.4.2. Acute Mania
    • 5.4.3. Maintenance Therapy
    • 5.4.4. Treatment-Resistant Bipolar Disorder
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Johnson & Johnson Innovative Medicine
  • 6.2. Vanda Pharmaceuticals
  • 6.3. Otsuka Pharmaceutical
  • 6.4. Alzamend Neuro
  • 6.5. AbbVie

7. LIST OF TABLES

8. LIST OF FIGURES